Molecular profiles and genomic therapy in young vs. average-onset gastrointestinal (GI) cancers: A Czech national precision medicine network study, GENESIS
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F25%3A00143318" target="_blank" >RIV/00216224:14110/25:00143318 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.sciencedirect.com/journal/annals-of-oncology/vol/36/suppl/S2?page=9" target="_blank" >https://www.sciencedirect.com/journal/annals-of-oncology/vol/36/suppl/S2?page=9</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Molecular profiles and genomic therapy in young vs. average-onset gastrointestinal (GI) cancers: A Czech national precision medicine network study, GENESIS
Popis výsledku v původním jazyce
Background Young adults (YA) with GI cancers represent a biologically distinct subgroup. This study examined differences in genomic profiles and indications for genomically driven therapy (GDT) between YA and average-onset (AO) patients across GI cancer types. Methods Data from 625 advanced GI cancer patients enrolled in the Czech national precision medicine platform GENESIS were analyzed. Patients were stratified as YA if aged 20–49 years(y), or AO (≥50 y). A molecular tumor board made GDT recommendations based on NGS comprehensive genomic profiling. Genomic alterations (GA), clinically relevant variants (CRV), and GDT implementation were compared.
Název v anglickém jazyce
Molecular profiles and genomic therapy in young vs. average-onset gastrointestinal (GI) cancers: A Czech national precision medicine network study, GENESIS
Popis výsledku anglicky
Background Young adults (YA) with GI cancers represent a biologically distinct subgroup. This study examined differences in genomic profiles and indications for genomically driven therapy (GDT) between YA and average-onset (AO) patients across GI cancer types. Methods Data from 625 advanced GI cancer patients enrolled in the Czech national precision medicine platform GENESIS were analyzed. Patients were stratified as YA if aged 20–49 years(y), or AO (≥50 y). A molecular tumor board made GDT recommendations based on NGS comprehensive genomic profiling. Genomic alterations (GA), clinically relevant variants (CRV), and GDT implementation were compared.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30230 - Other clinical medicine subjects
Návaznosti výsledku
Projekt
—
Návaznosti
—
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů